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Background
Sustained HCV clearance after pegIFN-RBV is less frequent
in HIV-positive (-pos) than in HIV-negative (-neg) indi-
viduals. Less information exists about the rate of HCV
relapses and timing for recurrence of HCV viremia upon
completion of therapy in these two populations.
Methods
Retrospective analysis of all IFN-naïve patients with
chronic hepatitis C who received a full course of 48 weeks
of pegIFN (alpha 2a or 2b, at standard doses) plus weight-
adjusted RBV (~13 mg/kg, 1,000–1,200 mg/day) therapy
and had negative serum HCV-RNA at the end of treatment
(EOT). Incidence and timing for HCV relapse were ana-
lyzed separately in HIV-pos and HIV-neg patients. Serum
HCV-RNA was measured at EOT and every 3 months
thereafter during the next year using a real-time PCR assay
(Cobas Taqman, Roche), which has a lower limit of detec-
tion of 10 IU/mL.
Summary of results
A total of 610 patients treated with pegIFN-RBV were ret-
rospectively identified; 390 (64%) HIV-pos and 220
(36%) HIV-neg. A total of 253 (41%) patients achieved
EOT response (ITT analysis); 152 HIV-pos (39%) and 101
HIV-neg (46%) patients (p = 0.03). At EOT, main differ-
ences between HIV-pos vs. HIV-neg patients were as fol-
lows: mean age (41 vs. 45 years-old, p < 0.01), male
gender (70% vs. 55%, p = 0.01) and HCV genotype 1–4
(58% vs. 79%, p < 0.01). HCV relapse occurred in 49
(32%) HIV-pos and in 26 (26%) HIV-neg subjects (p =
0.5). Timing for relapse was comparable in HIV-pos and
HIV-neg patients: 70% vs. 55% within 12 weeks following
EOT; 27% vs. 40% between week 12 and 24 following
EOT, respectively (p = 0.3). There were two patients (one
HIV-pos and one HIV-neg), who relapsed after week 24
following EOT. Re-infection was excluded in both cases by
phylogenetic analysis. HCV genotype influenced the rate
of relapse (more frequent in HCV-1/4 than in HCV-2/3),
but not timing for relapse.
Conclusion
While the proportion of patients achieving EOT is lower
in HIV-pos than HIV-neg, subsequent relapse occurs with
similar frequency in the two groups (~30%). The rate of
late relapses (≥week 12 upon completion of therapy) with
pegIFN-RBV is greater than formerly reported using IFN
monotherapy (2%, Zeuzem et al., J Hepatol 2003), regard-
less of HIV status. The use of RBV may not only reduce the
risk for relapse (Shiffman et al., Hepatology 2007) but also
delay timing for relapses upon completion of hepatitis C
therapy. Therefore, 24 weeks of follow-up following EOT
are warranted to ensure the achievement of sustained
HCV clearance in most cases.
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